Bone Biologics 

$20
28
+$0+0% Today

Statistics

Day High
20
Day Low
20
52W High
90
52W Low
1.02
Volume
35,681
Avg. Volume
-
Mkt Cap
35.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-3.24
-2.27
-1.29
-0.32
Expected EPS
-0.54
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.65MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BBLGW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stryker
SYK
Mkt Cap129.89B
Stryker Corporation is a leading medical technology company that offers a range of orthopedic products, competing directly with Bone Biologics in the bone repair and regeneration market.
Zimmer Biomet
ZBH
Mkt Cap18.22B
Zimmer Biomet Holdings, Inc. specializes in musculoskeletal healthcare, offering products that compete in the orthopedic sector, similar to Bone Biologics' offerings.
Medtronic
MDT
Mkt Cap111.97B
Medtronic plc provides medical technologies, services, and solutions, including bone healing and regeneration products, making it a competitor in the same space as Bone Biologics.
Boston Scientific
BSX
Mkt Cap91.83B
Boston Scientific Corporation offers products in various medical fields, including orthopedic surgery, competing with Bone Biologics in areas like bone growth and repair.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its subsidiary DePuy Synthes, offers a wide range of orthopedic products, directly competing with Bone Biologics in the field of bone health and regeneration.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, Inc., while primarily known for its biopharmaceutical products, has ventured into cell therapy, which could potentially compete with Bone Biologics' regenerative medicine approaches.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc., with its broad range of healthcare products, has the potential to compete in the orthopedic and regenerative medicine space, overlapping with Bone Biologics' market.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including treatments that could compete with Bone Biologics in bone health and regeneration.
AMGEN
AMGN
Mkt Cap189.22B
Amgen Inc. focuses on human therapeutics, including osteoporosis treatment and bone health products, making it a competitor in the bone regeneration market alongside Bone Biologics.

About

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Show more...
CEO
Mr. Jeffrey Frelick
Employees
2
Country
United States
ISIN
US0980701546

Listings

0 Comments

Share your thoughts

FAQ

What is Bone Biologics stock price today?
The current price of BBLGW is $20 USD — it has increased by +0% in the past 24 hours. Watch Bone Biologics stock price performance more closely on the chart.
What is Bone Biologics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bone Biologics stocks are traded under the ticker BBLGW.
What is Bone Biologics market cap?
Today Bone Biologics has the market capitalization of 35.9M
When is the next Bone Biologics earnings date?
Bone Biologics is going to release the next earnings report on June 03, 2026.
What were Bone Biologics earnings last quarter?
BBLGW earnings for the last quarter are -0.58 USD per share, whereas the estimation was -0.34 USD resulting in a -70.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bone Biologics revenue for the last year?
Bone Biologics revenue for the last year amounts to 0 USD.
What is Bone Biologics net income for the last year?
BBLGW net income for the last year is -14.65M USD.
How many employees does Bone Biologics have?
As of April 16, 2026, the company has 2 employees.
In which sector is Bone Biologics located?
Bone Biologics operates in the Health & Wellness sector.
When did Bone Biologics complete a stock split?
The last stock split for Bone Biologics was on June 07, 2023 with a ratio of 1:30.
Where is Bone Biologics headquartered?
Bone Biologics is headquartered in Burlington, United States.